Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

Business Wire • Feb 20, 2026

Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y

RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.

Zacks Investment Research • Jan 22, 2026

Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript

Seeking Alpha • Jan 21, 2026

Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Antihistamineeyedrop--Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once Daily Relief.

Business Wire • Jan 14, 2026

3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape

Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.

Zacks Investment Research • Dec 8, 2025

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.

Business Wire • Dec 2, 2025

Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds

Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, with North America lagging but Europe and emerging markets offsetting declines through acquisitions and new launches. Key growth drivers include upcoming biosimilar Abatacept and generic GLP-1 drugs, with launches expected to boost earnings beyond FY27 as Revlimid headwinds subside.

Seeking Alpha • Oct 29, 2025

Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues

RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.

Zacks Investment Research • Oct 27, 2025

Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council Conference Call Participants Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC Global Investment Research Bino Pathiparampil - Elara Securities (India) Private Limited, Research Division Saion Mukherjee - Nomura Securities Co. Ltd., Research Division Madhav Marda - Fidelity Investments Kunal Dhamesha - Macquarie Research Tushar Manudhane - Motilal Oswal Securities Limited, Research Division Kunal Randeria - Axis Capital Limited, Research Division Vivek Agrawal - Citigroup Inc., Research Division Harith Mohammed - Spark Institutional Equities Private Limited, Research Division Sumit Gupta - Centrum Broking Limited, Research Division Presentation Operator Good day, and welcome our quarter 2 fiscal year 2026 [indiscernible] Limited.

Seeking Alpha • Oct 24, 2025

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Seeking Alpha • Oct 6, 2025